User login
Key clinical point: The paclitaxel, carboplatin, and capecitabine (TCX) regimen offers a good efficacy and safety profile in patients with advanced gastric cancer.
Major finding: The patients had a median progression-free survival (PFS) and overall survival (OS) of 9.3 and 17.0 months, respectively; the PFS rates were 74.6%, 32.5%, and 14.4% and OS rates were 97.5%, 68.7%, and 21.7% at 6 months, 1 year, and 2 years, respectively. Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred only in 27.1%, 2.4%, and 1.2% of patients, respectively; non-hematologic and hematologic toxicities did not require intervention or treatment discontinuation.
Study details: This prospective cohort study included 83 patients with advanced gastric cancer who received the TCX regimen for ≥3 cycles.
Disclosures: No information on funding sources was provided. The author declared no conflicts of interest.
Source: Nguyen HT et al. Treatment outcome and safety of the TCX regimen for advanced gastric cancer: A prospective cohort study. Cancer Manag Res. 2022;14:2825-2837 (Sep 19). Doi: 10.2147/CMAR.S384325
Key clinical point: The paclitaxel, carboplatin, and capecitabine (TCX) regimen offers a good efficacy and safety profile in patients with advanced gastric cancer.
Major finding: The patients had a median progression-free survival (PFS) and overall survival (OS) of 9.3 and 17.0 months, respectively; the PFS rates were 74.6%, 32.5%, and 14.4% and OS rates were 97.5%, 68.7%, and 21.7% at 6 months, 1 year, and 2 years, respectively. Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred only in 27.1%, 2.4%, and 1.2% of patients, respectively; non-hematologic and hematologic toxicities did not require intervention or treatment discontinuation.
Study details: This prospective cohort study included 83 patients with advanced gastric cancer who received the TCX regimen for ≥3 cycles.
Disclosures: No information on funding sources was provided. The author declared no conflicts of interest.
Source: Nguyen HT et al. Treatment outcome and safety of the TCX regimen for advanced gastric cancer: A prospective cohort study. Cancer Manag Res. 2022;14:2825-2837 (Sep 19). Doi: 10.2147/CMAR.S384325
Key clinical point: The paclitaxel, carboplatin, and capecitabine (TCX) regimen offers a good efficacy and safety profile in patients with advanced gastric cancer.
Major finding: The patients had a median progression-free survival (PFS) and overall survival (OS) of 9.3 and 17.0 months, respectively; the PFS rates were 74.6%, 32.5%, and 14.4% and OS rates were 97.5%, 68.7%, and 21.7% at 6 months, 1 year, and 2 years, respectively. Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred only in 27.1%, 2.4%, and 1.2% of patients, respectively; non-hematologic and hematologic toxicities did not require intervention or treatment discontinuation.
Study details: This prospective cohort study included 83 patients with advanced gastric cancer who received the TCX regimen for ≥3 cycles.
Disclosures: No information on funding sources was provided. The author declared no conflicts of interest.
Source: Nguyen HT et al. Treatment outcome and safety of the TCX regimen for advanced gastric cancer: A prospective cohort study. Cancer Manag Res. 2022;14:2825-2837 (Sep 19). Doi: 10.2147/CMAR.S384325